Roscoe Medical, a Compass Health Brands Company

roscoemedical.com

Roscoe Medical, a Compass Health Brands Company, is committed to bringing to market innovative, high quality products that enable consumers to live healthier, more comfortable and independent lives. Through our national distribution network, we serve national, regional and independent wholesalers, distributors, and home medical equipment dealers as well as home healthcare providers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

GANNEX RECEIVED U.S. FDA FAST TRACK DESIGNATION FOR ITS NASH DRUG CANDIDATE ASC42,AN FXR AGONIST

Gannex | December 14, 2020

news image

Gannex, an entirely claimed organization of Ascletis Pharma Inc. (HKEX:1672) and completely committed to the R&D and commercialization of new medications in the field of NASH, reported today that it got Fast Track assignment from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug applicant ASC42. The U.S. FDA's Fast Track advancement program is intended to encourage the turn of events and speed up the survey of medications that ha...

Read More

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

news image

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More

Pharmacy Market

AIKIDO PHARMA REPORTS IMPROVED MANUFACTURING PROCESS AND NEW UNITED STATES PATENT FOR PANCREATIC DRUG

AIkido Pharma Inc. | March 04, 2022

news image

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Read More

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

news image

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More
news image

Pharma Tech

GANNEX RECEIVED U.S. FDA FAST TRACK DESIGNATION FOR ITS NASH DRUG CANDIDATE ASC42,AN FXR AGONIST

Gannex | December 14, 2020

Gannex, an entirely claimed organization of Ascletis Pharma Inc. (HKEX:1672) and completely committed to the R&D and commercialization of new medications in the field of NASH, reported today that it got Fast Track assignment from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug applicant ASC42. The U.S. FDA's Fast Track advancement program is intended to encourage the turn of events and speed up the survey of medications that ha...

Read More
news image

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More
news image

Pharmacy Market

AIKIDO PHARMA REPORTS IMPROVED MANUFACTURING PROCESS AND NEW UNITED STATES PATENT FOR PANCREATIC DRUG

AIkido Pharma Inc. | March 04, 2022

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Read More
news image

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us